Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DNM1L | O00429 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009892 | 0.92 | CACNA1G (0.37) | CACNA1GCACNA1HCACNA1IHRH3OGA | |
| SCHEMBL3018214 | 0.92 | CACNA1G (0.37) | CACNA1GCACNA1HCACNA1IHRH3OGA | |
| SCHEMBL3013690 | 0.89 | FABP4 (0.37) | CACNA1GCACNA1HCACNA1IHRH3OGA | |
| SCHEMBL3007229 | 0.89 | ALDH1A1 (0.34) | CACNA1GCACNA1HCACNA1IHRH3OGA | |
| SCHEMBL3006880 | 0.88 | OGA (0.36) | HRH3OGASMN1; SMN2DNM1LALDH1A1 | |
| SCHEMBL3009855 | 0.88 | HRH3 (0.34) | HRH3OGANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3016738 | 0.88 | SMN1; SMN2 (0.36) | HRH3OGANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3004517 | 0.88 | LMNA (0.37) | CACNA1GCACNA1HCACNA1IHRH3OGA | |
| SCHEMBL3012900 | 0.87 | DNM1L (0.37) | HRH3OGADNM1LALDH1A1LMNA | |
| SCHEMBL3019281 | 0.87 | HRH3 (0.35) | HRH3OGARAB9ASMN1; SMN2DNM1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | CACNA1G 3093/4885CACNA1H 3804/4885CACNA1I 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.